Innovent Biologics, Inc. announces that results of a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications.
Innovent Biologics, Inc. announces that results of a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications.